Table 1. Subject Statistics.

Subject Group	Total	IPSS Low	Int-1	Int-2	High	M	F	Age5/Years Median (Range)
(a) Stage I1
s-MDS	37	7	25	4	1	37	-	69 (49–87)
t-MDS	22	2	1	10	5	22	-	67 (44–80)
AML post MDS	16					16	-	73.5 (54–86)
Total Patients	75	9	26	14	6	75	-	70 (44–87)
Healthy	34						-	61 (52–79)
(b) Stage II2,3,4
s-MDS	119	33	68	15	2	60	59	68 (31–87)
t-MDS	42	4	6	16	13	30	12	69.5 (44–93)
AML post MDS	43					32	11	69 (47–86)
Total Patients	204	37	74	31	15	122	82	69 (31–96)
Healthy	112					58	54	56 (23–79)

¹Stage I IPSS Classification Data Available for 55 MDS Patients.

²Stage II IPSS Classification Data Available for 157 MDS Patients.

³Stage II aggregates included samples from Stage I subjects, except 1 t-MDS sample. N.B. No statistically significant batch effects between Stage I and Stage II samples were found, as ascertained by analysis of variance analysis.

⁴60 patients (22 t-MDS and 38 s-MDS) received various treatments. The treatment was found not to be a statistically significant factor in classification for proteins of interest.

⁵Age differences between patients and healthy controls were not statistically different for reported results.